L-NAME Hydrochloride: NOS Inhibition for Vascular Tone and Hypertension Research

Executive Summary: L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is a potent and selective inhibitor of nitric oxide synthase (NOS), with an IC₅₀ of approximately 70 μM under standard in vitro conditions (APExBIO product data). By reducing nitric oxide (NO) synthesis, it enables targeted interrogation of NO-dependent vascular, neuronal, and inflammatory signaling pathways. L-NAME Hydrochloride induces dose-dependent increases in systemic blood pressure in vivo, reversible by L-arginine supplementation (Yamada et al. 2010). The compound is highly soluble in water (≥27 mg/mL) and DMSO (≥23 mg/mL), but insoluble in ethanol, with optimal storage at -20°C. APExBIO provides L-NAME Hydrochloride (SKU A7088) for research applications requiring robust and reproducible NOS inhibition.

Biological Rationale

Nitric oxide (NO) is a gaseous signaling molecule produced endogenously by three main isoforms of nitric oxide synthase (NOS): endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). NO regulates vascular tone, neurotransmission, immune defense, and gene expression (see mechanisms review). In the vasculature, NO mediates smooth muscle relaxation and opposes vasoconstriction. Dysregulated NO production is implicated in hypertension, atherosclerosis, and inflammatory disorders. Pharmacological inhibition of NOS—specifically via L-NAME Hydrochloride—enables controlled study of NO's role in these physiological and disease processes.

Mechanism of Action of L-NAME Hydrochloride

L-NAME Hydrochloride acts as a competitive, substrate-analog inhibitor of NOS enzymes, binding to the L-arginine site. By occupying this site, L-NAME blocks the conversion of L-arginine to NO and citrulline. This inhibition is dose-dependent, with reported IC₅₀ values near 70 μM for eNOS under cell-free assay conditions (APExBIO). In tissues, L-NAME reduces NO-mediated signaling, leading to decreased vasodilation and increased vascular resistance. In live animal models, intravenous or chronic oral L-NAME administration induces hypertension, bradycardia, and endothelial dysfunction, effects that are reversible by L-arginine supplementation (Yamada et al. 2010).

Evidence & Benchmarks

• L-NAME Hydrochloride inhibits NOS activity with an IC₅₀ of ~70 μM in cell-free assays (APExBIO, product page).
• In isolated porcine aortic tissue, 1 mM L-NAME inhibits Ca²⁺-dependent endothelial NOS and shifts acetylcholine-mediated relaxation to contraction (Yamada et al. 2010).
• Intravenous L-NAME (10–50 mg/kg) in rats produces dose-dependent increases in systemic blood pressure and bradycardia, reversible by L-arginine (Yamada et al. 2010).
• L-NAME does not significantly block rapakinin-induced vasorelaxation in SHRs, indicating its specificity for NO-mediated pathways (Yamada et al. 2010, Table 1).
• L-NAME is soluble at ≥27 mg/mL in water and ≥23 mg/mL in DMSO; insoluble in ethanol (APExBIO, product page).

This article extends prior guides (Endothelin-1.com, which details troubleshooting workflows) by providing an updated synthesis of evidence on dose parameters and mechanistic selectivity. For a review of advanced mechanistic insights, see Flunarizinelab.com; this article adds recent cross-validation with peptide-based vasorelaxation models. For scenario-driven protocols, consult Tolrestatonline.com.

Applications, Limits & Misconceptions

L-NAME Hydrochloride is a reference compound for:

• Vascular tone regulation studies: Dissection of NO-dependent relaxation and contraction in isolated vessel rings (Yamada et al. 2010).
• Hypertension research: Induction of experimental hypertension and endothelial dysfunction in rodents.
• NO signaling pathway mapping: Analysis of NOS inhibition on gene expression and post-translational modifications.
• Cellular stress models: Inhibition of NO and downstream pathways (iNOS, COX-2, PGE₂) in high-glucose or inflammatory contexts.
• Cardiovascular disease models: Elucidation of NO's role in atherosclerosis and vascular remodeling (Endothelin-1.com).

Common Pitfalls or Misconceptions

• Not all vasorelaxation is NO-dependent: L-NAME does not block responses mediated by non-NO mechanisms (e.g., prostaglandin I₂ or CCK1 receptor pathways) (Yamada et al. 2010).
• L-NAME is not isoform-selective: It inhibits eNOS, nNOS, and iNOS similarly at high concentrations.
• Solubility limits: Insoluble in ethanol; must be dissolved in water or DMSO for biological assays (APExBIO).
• Reversibility: L-arginine supplementation can reverse L-NAME's effects, which may confound chronic studies.
• Non-therapeutic use: L-NAME Hydrochloride is for research only, not for clinical or diagnostic purposes.

Workflow Integration & Parameters

For cell culture, L-NAME is typically used at 1 mM for 24–72 hours to inhibit NO production in endothelial, neuronal, or immune cells (APExBIO). In animal studies, intravenous dosing ranges from 10–50 mg/kg, with hypertension induction observable within minutes. Solutions should be prepared fresh and used promptly; extended storage may degrade activity. The compound is supplied as a solid for reconstitution. For workflow reproducibility, APExBIO’s A7088 kit includes validated purity and solubility specifications (product page).

Conclusion & Outlook

L-NAME Hydrochloride remains the benchmark NOS inhibitor for dissecting NO-dependent physiology and pathophysiology. Its well-characterized mechanism, robust solubility, and reversibility make it essential for vascular, neurobiological, and metabolic research. Future applications include combinatorial studies with selective COX inhibitors or receptor antagonists to map non-NO vasorelaxation pathways. For detailed protocols and troubleshooting, refer to the APExBIO product page and related scenario-based guides (APExBIO A7088, Gestrinonesupply.com).